OBP 2011
Alternative Names: OBP-2011Latest Information Update: 01 Mar 2023
At a glance
- Originator Kagoshima University
- Developer Oncolys BioPharma
- Class Antivirals
- Mechanism of Action Nucleocapsid protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical COVID 2019 infections
Most Recent Events
- 17 Aug 2021 Preclinical trials in COVID-2019 infections in Japan (PO) before August 2021 (Oncolys pipeline, August 2021)